A Phase 3, Open-Label Study to Evaluate Safety and Efficacy of Epcoritamab in Combination With Rituximab and Lenalidomide (R2) Compared to R2 in Subjects With Relapsed or Refractory Follicular Lymphoma (EPCORE FL-1)

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 25 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Epcoritamab (Primary) ; Lenalidomide; Rituximab
Indications Follicular lymphoma
Focus Registrational; Therapeutic Use
Acronyms EPCORE FL-1
Sponsors AbbVie; AbbVie Germany; Genmab

Most Recent Events

05 Feb 2025 Status changed from recruiting to active, no longer recruiting.
04 Dec 2024 Planned End Date changed from 16 Jun 2030 to 1 Oct 2030.
04 Dec 2024 Planned primary completion date changed from 15 Nov 2029 to 1 Oct 2030.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight